Natcher Conference Center Research Articles

Coming Up…

The NIA‐NIAAA workshop on “Role of Alcohol Misuse in the Onset and Progression of Alzheimer's Disease and Its Related Dementias” will be a hybrid event held July 26‐27 in the Natcher Conference Center on the NIH Campus, in Bethesda, Maryland. For more information, go to https://www.nia.nih.gov/research

Proceedings of the Food and Drug Administration's public workshop on new red blood cell product regulatory science 2016.

The US Food and Drug Administration (FDA) held a workshop on red blood cell (RBC) product regulatory science on October 6 and 7, 2016, at the Natcher Conference Center on the National Institutes of Health (NIH) Campus in Bethesda, Maryland. The workshop was supported by the National Heart, Lung, and Blood Institute, NIH; the Department of Defense; the Office of the Assistant Secretary for Health, Department of Health and Human Services; and the Center for Biologics Evaluation and Research, FDA. The workshop reviewed the status and scientific basis of the current regulatory framework and the available scientific tools to expand it to evaluate innovative and future RBC transfusion products. A full record of the proceedings is available on the FDA website (http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm507890.htm). The contents of the summary are the authors' opinions and do not represent agency policy.

Implications of HIV PrEP Trials Results

Abstract Six randomized clinical trials have been implemented to examine the efficacy of tenofovir disoproxil fumarate (TDF) and/or TDF/emtricitabine (TDF/FTC) as preexposure prophylaxis for HIV-1 infection (PrEP). Although largely complementary, the six trials have many similar features. As the earliest results become available, an urgent question may arise regarding whether changes should be made in the conduct of the other trials. To consider this in advance, a Consultation on the Implications of HIV Pre-Exposure Prophylaxis (PrEP) Trials Results sponsored by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and the Bill and Melinda Gates Foundation (BMGF) was held on January 29, 2010, at the Natcher Conference Center, NIH, Bethesda, MD. Participants included basic scientists, clinical researchers (including investigators performing the current PrEP trials), and representatives from the U.S. Food and Drug Administration (FDA) and the agencies sponsoring the trials: the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Agency for International Development (USAID), the BMGF, and the U.S. NIH. We report here a summary of the presentations and highlights of salient discussion topics from this workshop.

Conference Scene: Wake-Up Call for The Engineering and Biomedical Science Communities in Nanomedicine

The IEEE-NIH 4th Life Science Systems and Applications Workshop 2009 (LiSSA '09) was jointly organized by the IEEE LiSSA Technical Committee and the NIH Nano Task Force. It was endorsed by the NIH Biomedical Information Science and Technology Initiative (BISTI) and the National Library of Medicine. The workshop was held in the Natcher Conference Center on the NIH campus in Bethesda, MD, USA. It took place on the 9-10 April, 2009, during the NIH NanoWeek and had approximately 200 delegates from around the globe (including North America, Europe, Asia and Australia) from both engineering and biomedical science disciplines. The conference featured around 40 talks, including nine plenary speakers emphasizing current state-of-the-art nanotechnology practices, developments and industry applications. All talks were scheduled in three oral and seven special sessions, as well as three breakout sessions. In addition, the interactive poster sessions hosted over 30 abstracts and attracted much attention from the audience; these sessions were readily used by many attendees to connect with colleagues of similar interest. In this article, we provide some of the highlights from the workshop.

Human Disease Glycomics/Proteome Initiative (HGPI)

Human Disease Glycomics/Proteome Initiative (HGPI)

Frontiers in Glycomics; Bioinformatics and Biomarkers in Disease September 11‐13, 2006 Natcher Conference Center, NIH Campus, Bethesda, MD, USA

This is a short summary of a meeting entitled "The Frontiers in Glycomics; Bioinformatics and Biomarkers in Disease" which was jointly organized by the NIH Consortium for Functional Glycomics (CFG), Human Disease Glycomics/Proteome Initiative (HGPI), National Cancer Institute, National Institute of General Medical Sciences, Japan Society for the Promotion of Science and National Center for Research Resources held at the NIH Campus, Bethesda, MD, Natcher Conference Center in September 11-13, 2006.

National Institutes of Health, State-of-the-Science Conference on Management of Menopause-Related Symptoms, March 21–23, 2005, NIH Natcher Conference Center, Bethesda, Maryland

National Institutes of Health, State-of-the-Science Conference on Management of Menopause-Related Symptoms, March 21–23, 2005, NIH Natcher Conference Center, Bethesda, Maryland

National Institutes of Health State-of-the-Science Conference on Management of Menopause-Related Symptoms, March 21–23, 2005 NIH Natcher Conference Center Bethesda, Maryland

National Institutes of Health State-of-the-Science Conference on Management of Menopause-Related Symptoms, March 21–23, 2005 NIH Natcher Conference Center Bethesda, Maryland

Conference report: functional magnetic resonance imaging for beginners--a review of the fMRI experience IV, 13-14 May 2002, Natcher Conference Center, National Institutes of Health, Bethesda, MD.

The fourth fMRI Experience meeting was held at the Bethesda, Maryland campus of the National Institutes of Health on May 13th and 14th, 2002. The purpose of the meeting was to provide a platform for students working with functional magnetic resonance imaging (fMRI) to present their research to an international audience of peers. This year’s meeting featured special lectures from Dr. Leslie Ungerleider (“Imaging Mechanisms of Visual Attention”) and Dr. Daniel Weinberger (“Genetic Variation and fMRI Response”).

NCI Image Archive Management Workshop: A Preliminary Report

The National Cancer Institute organized a workshop entitled “Image Archive Management” that was presented on August 28 and 29, 2000, at the Natcher Conference Center on the National Institutes of Health (NIH) campus. The purpose of this workshop was to solicit expert input for the planned development of an archival system to make imaging databases readily accessible by the broad scientific community. The specific goals were to ( a) define the technical requirements for a virtual archive of images used in oncology, ( b) define the policy issues for access to these images, ( c) recommend a process and phases for implementation of a robust imaging archival system, ( d) review how this effort could be expanded and coupled with other ongoing efforts by NIH and other organizations interested in imaging, and ( e) form an overall plan and policy to allow interoperability of image data archives. Representatives who attended the workshop came from academia, government agencies, and large and small businesses. A preliminary report was generated, as outlined herein, and additional reports are anticipated from the steering committee being organized as one of this workshop's recommendations, which is expected to be active by summer 2001. Additional information, including the list of participants in this workshop, is available at the Biomedical Imaging Program Web site ( http://www.nci.nih.gov/bip/ ).

Conference Report Bioengineering in the Millennium: National Institute of Health Symposium Bioengineering-Building the Future of Biology and Medicine

National Institute of Health (NIH) held the first of its kind bioengineering symposium in Bethesda, Maryland (USA) from 27–28 February 1998 at the Natcher Conference Center. This symposium was organized to chart die vision for the future of bioengineering research in the 21st century.

Hepatic drug delivery and gene therapy

On September 21-22, 1995, an international meeting entitled "Targeting of Novel Therapeutics to the Liver and GI Tract" was held at the Natcher Conference Center on the campus of the National Institutes of Health. The conference was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases through the Division of Digestive Diseases and Nutrition and Digestive Diseases Interagency Coordinating Committee (DDICC). Section 440A of Public Law 94-562 in 1976 created the DDICC for the purpose of coordinating the digestive disease-related research activities of relevant federal health agencies into a coordinated program aimed at combating digestive diseases. As part of this federal effort, an assessment of the "state of the art" for targeted drug therapeutics to the liver and gene therapy was undertaken through the conference, cochaired by Dr. Mark Zern (Thomas Jefferson Medical College) and Dr. Flossie Wong-Staal (University of California, San Diego, CA). The conference was divided into four sessions: Session I was Vectors and Techniques; Session II was Liver and Metabolic Diseases; Session III was Hepatitis and GI Disease; and Session IV was Approaches for HIV Infection. This summary focuses on the new technologies and the studies directly pertaining to liver disease. Table 1 lists the techniques and their applications. Table 2 describes viral vectors that have been employed for the purpose of hepatic gene therapy. Table 3 summarizes the studies presented as posters at the conference.(Hepatology 1997 Feb;25(2):484-91)

Hepatic drug delivery and gene therapy.

On September 21-22, 1995, an international meeting entitled "Targeting of Novel Therapeutics to the Liver and GI Tract" was held at the Natcher Conference Center on the campus of the National Institutes of Health. The conference was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases through the Division of Digestive Diseases and Nutrition and Digestive Diseases Interagency Coordinating Committee (DDICC). Section 440A of Public Law 94-562 in 1976 created the DDICC for the purpose of coordinating the digestive disease-related research activities of relevant federal health agencies into a coordinated program aimed at combating digestive diseases. As part of this federal effort, an assessment of the "state of the art" for targeted drug therapeutics to the liver and gene therapy was undertaken through the conference, cochaired by Dr. Mark Zern (Thomas Jefferson Medical College) and Dr. Flossie Wong-Staal (University of California, San Diego, CA). The conference was divided into four sessions: Session I was Vectors and Techniques; Session II was Liver and Metabolic Diseases; Session III was Hepatitis and GI Disease; and Session IV was Approaches for HIV Infection. This summary focuses on the new technologies and the studies directly pertaining to liver disease. Table 1 lists the techniques and their applications. Table 2 describes viral vectors that have been employed for the purpose of hepatic gene therapy. Table 3 summarizes the studies presented as posters at the conference.

Directed to defend its raison d'etre, NIH holds communications conference

"THE CROWN JEWEL of the federal government" wants a little lapidary attention. Physician-author Lewis Thomas' sparkling reference to the National Institutes of Health notwithstanding, the NIH held a 2-day conference seeking ways to polish its public image. The meeting, entitled "NIH: Communicating Science and Health in the New Millennium," brought together some 200 research-oriented participants and media-savvy panelists to discuss how to make all Americans more aware of what their tax dollars accomplish. The event inaugurated the Natcher Conference Center, a brand-new administration and auditorium—containing addition to the Bethesda, Md, campus on which most of the 17 institutes, offices, and other NIH components, such as the National Library of Medicine and National Center for Human Genome Research, pursue their aims. The unprecedented gathering was held in response to concern expressed last year by the House Appropriations Committee that important research advances were not being made known to the public. NIH